Close Menu

NEW YORK – Oncocyte said on Thursday that it is collaborating with the Fondazione Michelangelo in Milan, Italy to evaluate the company's DetermaIO test as a therapy response predictor in the NeoTRIPaPDL1 trial.

DetermaIO is a tissue-based gene expression assay, designed to evaluate signals associated with the tumor immune microenvironment. The test stratifies patients according to their likelihood of responding to immunotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.